Lectin complement pathway initiators after subarachnoid hemorrhage - an observational study.
Delayed cerebral ischemia
Ficolin
Functional outcome
Lectin complement pathway
Subarachnoid hemorrhage
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
12 Nov 2020
12 Nov 2020
Historique:
received:
11
08
2020
accepted:
05
10
2020
entrez:
13
11
2020
pubmed:
14
11
2020
medline:
27
8
2021
Statut:
epublish
Résumé
This exploratory study investigated the time-course of lectin complement pathway (LCP) initiators in cerebrospinal fluid (CSF) and plasma in patients with subarachnoid hemorrhage (SAH), as well as their relationship to delayed cerebral ischemia (DCI) and functional outcome. Concentrations of ficolin-1, ficolin-2, ficolin-3, and mannose-binding lectin (MBL) were analyzed in CSF and plasma from patients with SAH. Samples were collected daily from admission until day 9 (CSF; N_ On admission, CSF levels of all LCP initiators were increased in SAH patients compared with healthy controls. Levels declined gradually over days in patients; however, a biphasic course was observed for ficolin-1. Increased CSF levels of all LCP initiators were associated with a poor functional outcome in univariate analyses. This relationship persisted for ficolin-1 and MBL in multivariate analysis after adjustments for confounders (age, sex, clinical severity, distribution and amount of blood on CT-imaging) and multiple testing (1.87 ng/mL higher in average, 95% CI, 1.17 to 2.99 and 1.69 ng/mL higher in average, 95% CI, 1.09 to 2.63, respectively). In patients who developed DCI compared with those without DCI, CSF levels of ficolin-1 and MBL tended to increase slightly more over time (p_interaction = 0.021 and 0.033, respectively); however, no association was found after adjustments for confounders and multiple testing (p-adj_interaction = 0.086 and 0.098, respectively). Plasma ficolin-1 and ficolin-3 were lower in SAH patients compared with healthy controls on all days. DCI and functional outcome were not associated with LCP initiator levels in plasma. Patients with SAH displayed elevated CSF levels of ficolin-1, ficolin-2, ficolin-3, and MBL. Increased CSF levels of ficolin-1 and MBL were associated with a poor functional outcome. This study was a retrospective analysis of samples, which had been prospectively sampled and stored in a biobank. Registered at clinicaltrials.gov ( NCT01791257 , February 13, 2013, and NCT02320539 , December 19, 2014).
Sections du résumé
BACKGROUND
BACKGROUND
This exploratory study investigated the time-course of lectin complement pathway (LCP) initiators in cerebrospinal fluid (CSF) and plasma in patients with subarachnoid hemorrhage (SAH), as well as their relationship to delayed cerebral ischemia (DCI) and functional outcome.
METHODS
METHODS
Concentrations of ficolin-1, ficolin-2, ficolin-3, and mannose-binding lectin (MBL) were analyzed in CSF and plasma from patients with SAH. Samples were collected daily from admission until day 9 (CSF; N_
RESULTS
RESULTS
On admission, CSF levels of all LCP initiators were increased in SAH patients compared with healthy controls. Levels declined gradually over days in patients; however, a biphasic course was observed for ficolin-1. Increased CSF levels of all LCP initiators were associated with a poor functional outcome in univariate analyses. This relationship persisted for ficolin-1 and MBL in multivariate analysis after adjustments for confounders (age, sex, clinical severity, distribution and amount of blood on CT-imaging) and multiple testing (1.87 ng/mL higher in average, 95% CI, 1.17 to 2.99 and 1.69 ng/mL higher in average, 95% CI, 1.09 to 2.63, respectively). In patients who developed DCI compared with those without DCI, CSF levels of ficolin-1 and MBL tended to increase slightly more over time (p_interaction = 0.021 and 0.033, respectively); however, no association was found after adjustments for confounders and multiple testing (p-adj_interaction = 0.086 and 0.098, respectively). Plasma ficolin-1 and ficolin-3 were lower in SAH patients compared with healthy controls on all days. DCI and functional outcome were not associated with LCP initiator levels in plasma.
CONCLUSION
CONCLUSIONS
Patients with SAH displayed elevated CSF levels of ficolin-1, ficolin-2, ficolin-3, and MBL. Increased CSF levels of ficolin-1 and MBL were associated with a poor functional outcome.
TRIAL REGISTRATION
BACKGROUND
This study was a retrospective analysis of samples, which had been prospectively sampled and stored in a biobank. Registered at clinicaltrials.gov ( NCT01791257 , February 13, 2013, and NCT02320539 , December 19, 2014).
Identifiants
pubmed: 33183322
doi: 10.1186/s12974-020-01979-y
pii: 10.1186/s12974-020-01979-y
pmc: PMC7661172
doi:
Substances chimiques
Biomarkers
0
Banques de données
ClinicalTrials.gov
['NCT01791257', 'NCT02320539']
Types de publication
Clinical Trial
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
338Subventions
Organisme : Rigshospitalet
ID : R170-A7495
Organisme : Rigshospitalet
ID : R212-2015-1987
Organisme : Danmarks Grundforskningsfond (DK)
ID : DFF-6110-00489
Références
J Immunol. 2010 Nov 1;185(9):5628-36
pubmed: 20870944
Neurochem Res. 2014 Feb;39(2):248-53
pubmed: 24309995
Stroke. 2017 Sep;48(9):2391-2398
pubmed: 28768799
Immunobiology. 2008;213(3-4):297-306
pubmed: 18406375
Neurology. 1998 May;50(5):1413-8
pubmed: 9595997
Mol Immunol. 2018 Oct;102:26-31
pubmed: 30007547
Scand J Immunol. 2013 Aug;78(2):181-93
pubmed: 23672641
Acta Neurol Scand. 2016 Nov;134(5):360-367
pubmed: 26792573
Immunol Rev. 2016 Nov;274(1):74-97
pubmed: 27782323
J Neuroinflammation. 2016 Jan 20;13:16
pubmed: 26792363
J Neurol Neurosurg Psychiatry. 1988 Nov;51(11):1457
pubmed: 3236024
Science. 1999 Jul 23;285(5427):595-9
pubmed: 10417391
Mol Immunol. 2008 May;45(10):2782-9
pubmed: 18343499
Stroke. 2010 Oct;41(10):2391-5
pubmed: 20798370
Mol Immunol. 2008 May;45(9):2660-6
pubmed: 18261799
J Neurol Neurosurg Psychiatry. 2007 Dec;78(12):1365-72
pubmed: 17470467
Neurology. 2014 Jan 14;82(2):126-34
pubmed: 24336142
BMC Infect Dis. 2017 Jan 4;17(1):7
pubmed: 28052761
Scand J Immunol. 2007 Apr;65(4):383-92
pubmed: 17386030
Mol Neurobiol. 2019 Jan;56(1):78-87
pubmed: 29675579
J Neurosurg. 2018 Nov 1;:1-10
pubmed: 30497171
Curr Atheroscler Rep. 2017 Oct 23;19(12):50
pubmed: 29063300
Neurocrit Care. 2019 Jun;30(Suppl 1):46-59
pubmed: 31144274
J Clin Neurophysiol. 2016 Jun;33(3):174-82
pubmed: 27258440
Stroke. 2000 May;31(5):1054-61
pubmed: 10797165
J Cereb Blood Flow Metab. 2019 May;39(5):794-807
pubmed: 29425056
BMJ. 2018 Jan 18;360:j5745
pubmed: 29348138
J Immunol. 2009 Dec 1;183(11):7371-8
pubmed: 19917686
J Neurol. 2018 Dec;265(12):2944-2948
pubmed: 30317466
Mol Immunol. 2014 Oct;61(2):149-52
pubmed: 25041699
Arterioscler Thromb Vasc Biol. 2018 Nov;38(11):2678-2690
pubmed: 30354247
Neurosci Lett. 2002 Jun 14;325(3):175-8
pubmed: 12044649
Stroke. 1988 May;19(5):604-7
pubmed: 3363593
PLoS One. 2013 May 31;8(5):e65151
pubmed: 23741476
Br J Anaesth. 2012 Sep;109(3):315-29
pubmed: 22879655
Mol Immunol. 2018 Oct;102:14-25
pubmed: 29933890
Circ Res. 2006 Jul 21;99(2):209-17
pubmed: 16778128
Mol Neurobiol. 2015 Feb;51(1):230-9
pubmed: 24691546
Eur J Immunogenet. 1992 Dec;19(6):403-12
pubmed: 1477092
Genes Immun. 2012 Oct;13(7):515-22
pubmed: 22673311
Scand J Immunol. 2009 Jun;69(6):555-62
pubmed: 19439017
Neurosurgery. 1980 Jan;6(1):1-9
pubmed: 7354892
Mol Neurobiol. 2017 Oct;54(8):6572-6580
pubmed: 27734336
EMBO J. 2015 Nov 12;34(22):2735-57
pubmed: 26489954
J Neuroinflammation. 2011 Dec 29;8:185
pubmed: 22206485
World Neurosurg. 2020 Mar;135:e541-e547
pubmed: 31863891
Stroke. 1986 Nov-Dec;17(6):1068-70
pubmed: 3810703